Saxenda Injection, Solution
NDC Package 50090-4257-0
Package Information
Saxenda (liraglutide) injection is sAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:•Adult patients with an initial body mass index (BMI) of [see Dosage and Administration (2.1)]:▪30 kg/m2 or greater (obese), or▪27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)• Pediatric patients aged 12 years and older with:▪body weight above 60 kg and▪an initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration (2.1)]Limitations of Use▪SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.▪The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.▪The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. This formulation utilizes a injection, solution delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-4257 and is authorized under FDA application NDA206321.
Identification & Billing
- RxCUI: 1598268 - Saxenda 6 MG/ML in 3 mL Weight Management Pen Injector
- RxCUI: 1598268 - Weight Management 3 ML liraglutide 6 MG/ML Pen Injector [Saxenda]
- RxCUI: 1598268 - 3 ML Saxenda 6 MG/ML Weight Management Pen Injector
- RxCUI: 1598268 - Saxenda 18 MG per 3 ML Weight Management Pen Injector
- RxCUI: 1598268 - Weight Management Saxenda 6 MG/ML Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-4257 - Saxenda
- 50090-4257-0 - 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
- 50090-4257 - Saxenda
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-4257-0 identifies a specific commercial package of 5 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Saxenda, a human prescription drug labeled by A-s Medication Solutions. This product is billed per "ML" milliliter and contains an estimated amount of 15 billable units per package. This injection, solution is formulated for subcutaneous use and contains liraglutide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on December 31, 2014. The current certification is valid through December 31, 2026.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090425700. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 15 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.